Published on : Sep 01, 2016
ALBANY, New York, September 01, 2016: A new market research report, titled “Osteoporosis Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Anabolic Therapies,” has been added by ResearchMoz.us to its comprehensive collection of research studies. The research study helps in understanding the present commercial and clinical landscape of the osteoporosis therapeutics market, focusing on the prognosis, diagnosis, and the numerous treatment options available at every phase of diagnosis.
According to the research report, in 2015, the Asia Pacific market for osteoporosis therapeutics was worth US$4.5 bn and is estimated to reach a value of US$7.7 bn by the end of 2022. The market is anticipated to register a progressive 7.80% CAGR between 2015 and 2022. The research report has made use of several tools in order to identify the current trends in the market, along with the potential growth opportunities. Historical data and estimated numbers have been given in the report to help the key players in designing their plans effectively in the near future.
Osteoporosis is considered as one of the most common metabolic bone diseases and is characterized by micro-architectural deterioration of bone tissue, low bone mass, and a subsequent rise in fracture risk. Osteoporosis is becoming a prominent public health problem across the globe, owing to which the market is estimated to witness significant growth in the next few years. The growing geriatric population is one of the prime factors estimated to fuel the growth of the Asia Pacific osteoporosis market throughout the forecast period.
Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=784620
The growing health insurance coverage for the elderly population and growing healthcare awareness among the population and policy makers are some of the key factors augmenting the growth of the osteoporosis market in Asia Pacific. In addition, the promising pipeline of the late-stage products is estimated to encourage the growth of the market in the coming few years. However, the growing competition from traditional medicines is projected to curb the growth of the market in the forecast period.
The osteoporosis market in Asia Pacific is getting inclined towards anabolic drug treatments from the traditional antiresorptive therapies in the last few years. The recent launch of new products and approval of drugs are estimated to encourage the growth of the overall market. These factors are further expected to create potential opportunities for the key players operating the Asia Pacific osteoporosis market in the next few years.
The research study throws light on the composition of the Asia Pacific osteoporosis market and offers a clinical comparison of the marketing therapies. It further analyzes the dominant therapies in terms of their commercial and clinical standing at present. The unmet needs of the market have also been highlighted in the research study in order to provide a competitive understanding of the gaps in the market.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]